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Despite an increasing understanding of the role of hemoglobin in ICH, it remains unclear how cells die in response to bleeding in the brain, which is crucial to develop effective therapeutic strategies. Classically, the research community distinguished between 2 modes of cell death, that is, apoptosis and necrosis. Both apoptotic and necrotic cells have been identified in animal models of ICH, 13, 14 as well as in the perihematoma region after surgical evacuation in humans. 15, 16 However, caution must be taken when attributing apoptosis or necrosis to single biochemical markers because these markers are not specific for one type of cell death. 17, 18 Moreover, recent studies discovered other forms of regulated nonapoptotic cell death, such as necroptosis and ferroptosis. 19, 20 To date, it is unclear to what extent the different forms of cell death contribute to ICH-induced toxicity.
In this study, we performed an unbiased screen of known pharmacological cell death inhibitors in hemoglobin-and hemin-induced toxicity in primary cortical neurons. We validated the identified cell death mechanisms using molecular markers in vitro and in vivo and performed electron microscopy to identify the morphological characteristics of ICHinduced cell death in vitro.
Materials and Methods
Chemicals and reagents are listed in the online-only Data Supplement.
Animals
Experimental procedures on mice were approved by the Weill Cornell Medicine Institutional Animal Care and Use Committee and conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines. Mice were purchased from Charles River Laboratories and housed at 68°F to 72°F, 30% to 70% humidity, under 12-hour light/dark cycle, with food (PicoLab Rodent diet 5053; LabDiet) and water freely accessible.
Mouse Model of ICH
ICH was induced in mice as previously described. 21 Male C57BL/6 mice (8-10 weeks old) were randomly assigned to groups.
Cell Culture
Primary cortical neurons were obtained from CD-1(ICR) mice at embryonic day 15 as previously described 22 and cultured at 37°C in a humidified 5% CO 2 atmosphere (density: 10 5 cells/well). Immortalized hippocampal neuroblasts (HT22 cells) were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 1% penicillin/streptomycin and treated when 70% confluent.
Cell Viability
We determined cell viability as previously described 23 at 14 to 18 hours after hemin or at 24 to 28 hours after hemoglobin exposure. Plates were measured at SpectraMax Plus Microplate Reader using SoftMax Pro v4.7.1 (both Molecular Devices, Sunnyvale, CA). We confirmed MTT assays (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; Promega, Madison, WI) by Live/Dead assay (Thermo Fisher Scientific, Waltham, MA) and fluorescence microscopy at Nikon Eclipse TS100 microscope using Nikon DS-L3 (Nikon Instruments, Melville, NY).
Immunoblot Analysis
We prepared protein extracts using 1% Triton buffer (25 mmol/L Tris pH 7.4, 100 mmol/L NaCl, 1 mmol/L EGTA, 1% Triton X-100, protease inhibitors, 2.5 mmol/L sodium orthovanadate). Samples were electrophoresed under reducing conditions on NuPAGE gels and transferred to nitrocellulose membrane. Antibodies against phospho extracellular signaling kinase 1/2 (ERK1/2), total ERK1/2, γ-tubulin, phospho-S166 receptor-interacting kinase 1 (RIP1), and β-actin were incubated overnight at 4°C. Secondary antibodies were incubated for 1 hour at room temperature. Proteins were detected using Odyssey infrared imaging system (LI-COR Biosciences).
RNA Extraction and Real-time Polymerase Chain Reaction
Total RNA was prepared using NucleoSpin RNA isolation kit according to established protocols. We performed real-time polymerase chain reaction using Taqman RNA-to-CT 1-Step Kit for mouse RIP1 (No. Mm00436354_m1) and RIP3 (Mm00444947_m1) at a 7500 Real-Time PCR System (Applied Biosystems). Expression levels were normalized to mouse β-actin endogenous control.
Electron Microscopy
Primary neurons were grown on poly-l-lysine-coated aclar plastic coverslips. We fixed the cells overnight at 4°C in 0.05 mol/L phosphate buffer (pH 7.4) containing 2% glutaraldehyde and 0.1 mol/L sucrose. The coverslips were processed for electron microscopy as previously described, with modifications. 24 We incubated the coverslips in 2% osmium tetroxide in phosphate buffer for 1 hour followed by embedding in Epon-812. Ultrathin sections (70 nm) using a Leica UC6 ultratome were collected on 400-mesh thin-bar copper grids (Electron Microscopy Sciences, Fort Washington, PA) and counterstained with 5% uranyl acetate and Reynold's lead citrate. Micrographs were taken on a Tecnai Biotwin transmission electron microscope (FEI, Hillsboro, OR). We quantified the percentage of cells displaying necrotic or apoptotic morphology (n=33-43/condition and replicate). Using ImageJ v.1.49 (http://imagej.nih.gov/ij/), we measured mitochondrial size as percentage area of total area of the cytoplasm 25 (comprising >1800 mitochondria in total). Analysis was performed by an investigator blinded to treatment group assignment.
Statistical Analysis
We evaluated normality by Kolmogorov-Smirnov test and variance homogeneity using Levené test. For normally distributed data with homogeneous variance, one-way analysis of variance followed by post hoc Bonferroni test was performed. When one of the criteria was not met, Kruskal-Wallis test was performed followed by post hoc Mann-Whitney U test with α-correction according to Bonferroni to adjust for the inflation of type I error because of multiple testing. Data are represented as mean±standard deviation (SD) except for nonparametric data, in which case medians are given. For electron microscopy data, mean±standard error of the mean (SEM) is given because this is the convention in this field. 
Results
Hemorrhagic Stroke In Vitro Shares Features of Ferroptotic and Necroptotic Cell Death
Lysis of red blood cells after ICH leads to release of hemoglobin, which is further broken down into heme or its oxidized form hemin. Hemoglobin or hemin have been used in vitro to study cell death in primary neurons and neuronal cell lines. 7, 21 Incubation of primary neurons with 100 μmol/L hemin led to a 50% reduction in cell survival ( Figure 1A ). This concentration is below the concentration estimated in vivo after ICH in humans. 
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In a systematic pharmacological characterization, we found that several chemical inhibitors that collectively define a ferroptotic form of cell death inhibited hemininduced death ( Figure 1A ). As with classically defined ferroptosis, 20 ,27 the canonical ferroptosis inhibitor Ferrostatin-1 protected against hemin toxicity. Moreover, other inhibitors of ferroptosis, including the iron chelator deferoxamine, the glutathione prodrug N-acetylcysteine, the water-soluble lipid peroxidation inhibitor Trolox, and the ERK1/2 inhibitor U0126 (but not its inactive control), abrogated hemin toxicity ( Figure 1B) .
Consistent with ferroptosis being a dominant mode of death, caspase inhibitors (that by definition inhibit apoptotic death 17 ), inhibitors of protein or mRNA synthesis, inhibitors or activators of autophagy did not increase cell viability in the presence of hemin ( Figure 1A ). Live/Dead assays, which represent a visible measure of cell death in single cells, revealed results that were similar to quantitative measurements of cell death performed with MTT assays ( Figure 1C ).
To statistically address whether hemin-induced neuronal death is ferroptotic, we compared the profile of chemical inhibitors of hemin toxicity with operationally defined ferroptosis. 20, 27 We found a large overlap; statistical analysis revealed that cell death induced by hemin in primary neurons can be considered ferroptotic (Fisher's exact test, twotailed P=1.00).
Unexpectedly, an inhibitor of necroptosis (Necrostatin-1), a regulated form of necrosis 19 and previously implicated in ischemic stroke, also blocked hemin-induced death ( Figure 1A through 1C). The specificity of this inhibitor against RIP1 was suggested by the observation that a structural analog (Necrostatin-1i), with no activity toward RIP1, did not block hemin-induced death.
Together, these studies suggested that hemin-induced death in cortical neurons shares features of ferroptosis and necroptosis. Convergence of these distinct modes of cell death in a single cell death paradigm has not been described.
To confirm that the present profile of protective inhibitors can protect generally from other potential toxins of lysed blood in addition to hemin, we examined whether inhibitors of ferroptosis and necroptosis could abrogate hemoglobininduced death. As expected from our hemin studies, inhibitors of ferroptosis and necroptosis abrogated hemoglobin-induced cell death (Figure 2) .
Together, these findings suggest that neurons exposed to hemoglobin or hemin die via a similar ferroptotic and necroptotic pathway.
Hemorrhagic Stroke In Vitro and In Vivo Shows Molecular Features of Ferroptosis and Necroptosis
We, thus, hypothesized that cell death after ICH in vitro is a mixture of ferroptosis and necroptosis. To establish the specificity of our chemical inhibitors, we assessed whether signaling molecules required for ferroptotic or necroptotic death were activated using biochemical measurements.
Activation of mitogen-activated protein (MAP) kinase signaling involving phospho-ERK1/2 is important in ferroptosis induced by erastin in tumor cells bearing oncogenic Ras. 28 We assessed whether ERK1/2 are activated by hemin in primary neurons evaluating total and phospho-ERK1/2 protein levels. We found an increase in phospho-ERK1/2 starting at 4 hours of hemin treatment ( Figure 3A ). As expected, this phosphorylation was inhibited by U0126, but not its inactive control U0124 ( Figure 3B ). Next, we wanted to confirm whether our in vitro findings translate to ICH in vivo. We found that phospho-ERK1/2 was significantly elevated at 6 and 24 hours after ICH in mice ( Figure 3C ). RIP1 and RIP3 mediate necroptotic cell death, and prior studies demonstrated an increase in RIP1 and RIP3 message in association with this type of death. 29, 30 Both RIP1 and RIP3 mRNA levels increased after hemin treatment and after ICH ( Figure 3D ). However, increases in RIP1 and RIP3 mRNA do not necessarily indicate enhanced necroptosis because both proteins, especially RIP1, have other functions that do not lead to necroptosis. 31, 32 It is established that RIP1 kinase activity is required to execute necroptosis. 33 Using an antibody against a known RIP1 autophosphorylation site at serine 166, 34 we found a Necrostatin-1-sensitive increase in phospho-RIP1 after hemin treatment ( Figure 3D ).
Hemorrhagic Stroke In Vitro Presents a Necrotic Morphology
Historically, distinct mechanisms of cell death were discriminated by their morphology at an ultrastructural level. Cells undergoing necrosis/necroptosis display swelling of organelles, structural loss of mitochondria, disruption of the plasma membrane, and subsequent release of intracellular content. By contrast, cells that die by apoptosis show cell shrinkage, nuclear fragmentation, and formation of apoptotic bodies. 17 In ferroptosis, shrunken mitochondria have been observed, while the plasma membrane remained intact, and formation of apoptotic bodies was absent. 20 To establish whether hemin toxicity involves ultrastructural features of necr(opt)osis and/or ferroptosis, we performed electron microscopy of primary neurons at 16 hours after hemin treatment. We chose this time because it is 8 hours before cell death has reached a steady state (24 hours), thus, increasing the likelihood to observe morphologies reflecting a continuum from early to late stages of death. Compared with vehicle treatment ( Figure 4A , upper row), some of the hemin-treated neurons displayed a necrotic morphology, as reflected by a loss of plasma membrane integrity and disintegration of organelles ( Figure 4A , middle row, left and middle). Other hemin-treated neurons presented an intact plasma membrane, but larger mitochondria ( Figure 4A , lower row, left and middle). Neuronal processes of hemin-treated cells were no longer intact ( Figure  4A , middle and lower row, right pictures). When we quantified the number of cells with either necrotic or apoptotic morphology, we found a significant increase in necrotic cells after hemin treatment, while we did not detect any apoptotic bodies ( Figure 4B ).
Because the sole positive morphological criterion for ferroptosis is shrunken mitochondria, we quantified mitochondrial size after hemin treatment. We did not find any shrunken mitochondria in any of the cells examined. In contrast, mean mitochondrial size was larger in hemin-treated cells, although not statistically significant ( Figure 4C) ; that is, the proportion of larger mitochondria increased, while that of smaller mitochondria decreased ( Figure 4D ).
Hemin Induces Regulated Necrosis in Cortical Neurons by Recruiting Both Ferroptotic and Necroptotic Cell Death Mechanisms
Because hemin-induced cell death shares pharmacological and molecular features of both ferroptosis and necroptosis, in the presence of ultrastructural features of necr(opt)osis, but not ferroptosis at 16 hours, we hypothesized that ferroptosis may induce an affector phase of death, leading to a necroptotic effector phase. If this were true, we predicted that the necroptosis inhibitor should have a longer therapeutic window than the ferroptosis inhibitors and that inhibiting ferroptosis should abrogate the increase in RIP1 and RIP3 gene expression and phospho-RIP1.
To assess the therapeutic window, primary neurons were treated with chemical inhibitors starting every 2 hours between 0 and 12 hours after hemin treatment. Necrostatin-1 was protective when added ≤8 hours. Similarly, Ferrostatin-1, Trolox, and U0126 abrogated hemin toxicity ≤8 hours. In contrast, the ferroptosis inhibitors N-acetylcysteine and deferoxamine 
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had shorter protective windows of 2 and 4 hours, respectively ( Figure 5A ). In line with the finding that the therapeutic window of Necrostatin-1 is not wider than that of the ferroptosis inhibitors, U0126 also failed to abrogate the increases in RIP1 ( Figure 5B ) and RIP3 ( Figure 5C ) gene expression and phospho-RIP1 ( Figure 5D ) after hemin treatment. Together, these data suggest that ferroptosis is not followed by downstream necroptosis in hemorrhagic stroke in vitro.
Alternatively, hemoglobin or hemin might elicit necroptotic (RIP1/3) or ferroptotic (phospho-ERK1/2) cell death mechanisms in parallel. If this is true, we expected that inhibition of both simultaneously would have an additive effect. Therefore, we investigated whether a subthreshold dose of U0126 would have an additive or synergistic effect on the dose-response of Necrostatin-1 protection. We found that addition of 0.5 μmol/L U0126 did not change the profile of protection by Necrostatin-1 ( Figure 6A and 6B). This suggests that there might be a common yet to be identified denominator onto which both ferroptosis and necroptosis converge, which then leads to neuronal necrosis ( Figure 6C ).
Discussion
The objective of this study was to use the leverage of an in vitro model of secondary injury in hemorrhagic stroke in cultured neurons to enhance understanding of cell death mechanisms after ICH that will allow more targeted and effective therapeutic strategies for this often fatal and highly morbid disease. We conclude that established toxic mediators from lysed blood, hemin, and hemoglobin, induced death in primary cortical neurons via features of ferroptotic or necroptotic cell death based on several criteria.
First, with the exception of cycloheximide, a panel of inhibitors of ferroptosis abrogated hemin-and hemoglobin-induced death (Figures 1 and 2) . The overlap between hemorrhagic stroke in vitro and ferroptosis in terms of pharmacological inhibitors was large enough that cell death induced by hemin in primary neurons can be considered ferroptotic. Second, biochemical features consistent with ferroptosis (enhanced phospho-ERK1/2) were observed in both in vitro and in vivo models of ICH (Figure 3 ). Of note, although shrunken mitochondria, a putative marker of ferroptosis, were not observed in our electron microscopy studies, we did observe ultrastructural features of necrosis/ Figure 4 ). In line with these morphological changes, the canonical necroptosis inhibitor, Necrostatin-1, but not its inactive analog prevented hemin-or hemoglobininduced death in cortical neurons (Figures 1 and 2) , and biochemical features of necroptosis (enhanced RIP1 and RIP3 mRNA expression and phospho-RIP1) were detected ( Figure 3) . Altogether, these data support the conclusion that experimental ICH induces cell death with features of ferroptosis and necroptosis.
necroptosis (
Our studies raised the possibility that hemin or hemoglobin induce a ferroptotic affector pathway of death, leading to a necroptotic effector phase of cell death ( Figure 6C ). Contrary to this model, however, the therapeutic window for the necroptosis inhibitor Necrostatin-1 was not wider than the ferroptotic inhibitors Ferrostatin-1 and U0126. Moreover, U0126 did not abrogate the increase in RIP1 and RIP3 gene expression or phospho-RIP1 after hemin treatment ( Figure 5 ). Although we cannot definitively exclude the possibility that the therapeutic window reflects differences in the time required for ferroptotic and necroptotic inhibitors to reach steady-state intracellular concentrations in vitro, the data suggest that necroptotic or ferroptotic signaling induced by hemin or hemoglobin is sufficient to reach a threshold of death that leads to neuronal necrosis. Inhibition of either one of these pathways can bring neurons below that threshold to survival ( Figure 6 ). To our knowledge, hemin and hemoglobin are the first death stimuli described to involve a mixture of necroptotic and ferroptotic features.
Ferroptosis has not previously been shown to mediate ICHinduced cell death. However, 4 genes induced by a ferroptotic stimulus in cancer cells ( 20 are also induced after ICH in mice. 35 Furthermore, Regan et al 36 demonstrated that hemin activates ERK1/2 in astrocytes. This is in line with our findings demonstrating an Values represent medians for hemin and mean±SD for hemoglobin. *P<0.05 vs hemin or hemoglobin alone. C, Three alternative hypotheses suggesting how hemoglobin or its breakdown product hemin induces cell death with ultrastructural features of necrosis: (1) Hemoglobin or hemin generate reactive lipid species (RLS), which increase phospho-ERK1/2. Phospho-ERK1/2 induces RIP1 that executes necroptotic cell death via RIP3. In this case, hemorrhagic stroke would induce ferroptosis as the affector phase of death, leading to a necroptotic effector phase. (2) Hemoglobin or hemin induces necroptotic (RIP1/3) and ferroptotic (phospho-ERK) cell death mechanisms independently, and these then converge at a yet to be identified common denominator into a necrotic morphology. (3) Hemoglobin or hemin induces necroptotic (RIP1/3) and ferroptotic (phospho-ERK) cell death mechanisms that independently lead to different types of regulated necrosis. Our data supports the second hypothesis. ERK1/2 indicates extracellular signaling kinase 1/2; NAC, N-acetylcysteine; Nec-1, Necrostatin-1; and RIP, receptor-interacting kinase.
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increase in phospho-ERK1/2 in neurons in vitro after hemin exposure and in vivo after ICH (Figure 3 ). Other studies support the idea that necroptosis is at least partly involved in ICH. In vitro, pretreatment with Necrostatin-1 protects astrocytes subjected to hemin treatment for 5 hours. 37 In a mouse model of ICH, intracerebroventricular administration of necrostatin-1 reduces cell death, brain edema, hematoma volumes, and neurological score deficits. 38 Moreover, expression of RIP3 increases after ICH, while pretreatment with Necrostatin-1 diminishes the interaction of RIP3 with RIP1 and ameliorates cell death after ICH. 39 Mice deficient in RIP3 show decreased cell death after ICH. 40 This is consistent with our findings that RIP1 and RIP3 gene expression as well as phospho-RIP1 levels are increased after ICH in vitro and in vivo (Figure 3) .
The apoptotic contribution to ICH-induced cell death has to date been unclear. Regan et al 36 showed that the pancaspase inhibitor z-VAD-fmk reduced cell death of cortical astrocytes at 4 hours but not at 8 hours after hemin treatment. Conversely, Laird et al 37 demonstrated that pretreatment with z-VAD-fmk failed to protect after 5 hours of hemin toxicity in cortical astrocytes. Co-treatment with z-VAD-fmk increased cellular viability of microvascular cells after 18 hours of hemin treatment. 41 In contrast, in human neuronlike cells exposed to hemin, z-VAD-fmk had no effect on cell viability. 42 While hemoglobin treatment of rat cortical neurons induced upregulation of cleaved caspase-3 and increased caspase-3-like enzyme activity, pretreatment with z-VAD-fmk and other caspase inhibitors did not prevent cell death. 43 After ICH in vivo, immunohistochemical expression of cleaved caspase-3 increased in rats 44 and mice 38 as did expression of apoptosis-related genes in rats. 45 Similarly, the role of autophagy after ICH is not clear. Yang et al 46 found that treatment of microglia with lysed blood in vitro resulted in toll-like receptor 4-mediated autophagy. Activated microglia caused neuronal death that was attenuated by 3-methyladenine. When administered intracerebroventricularly immediately after ICH onset, 3-methyladenine reduced microglia activation and brain damage. 46 Furthermore, ICH induced immunohistochemical expression of the autophagosome marker light chain 3-II (LC3-II) in mice. 38 Similarly, He et al 47 reported an increase in LC3-II, the lysosomal marker cathepsin D, and vacuole formation after ICH in rats.
Surprisingly, when we investigated the morphological phenotype of cell death after hemin-induced neuronal toxicity, we found a necrotic phenotype with swelling of organelles and cell bodies and disruption of the plasma membrane. We did not observe any shrunken mitochondria, characteristic for ferroptosis, or apoptotic bodies (Figure 4) . However, in animal models of ICH and in the perihematoma region after surgical evacuation in humans, both apoptotic and necrotic cells have been described. 13, 14 Because our morphological analysis was confined to hemin toxicity in neurons, the contribution of other cell death mechanisms in other cell types in vivo cannot be excluded.
The lack of protection by canonical, broad caspase inhibitors in neurons exposed to hemin, along with the necrotic morphology, seems to exclude apoptosis as a mechanism of death in vitro. Future studies will provide a head-to-head comparison of necroptotic, apoptotic, and ferroptotic inhibitors in vivo. It is likely that these studies will require intraventricular injections of drugs as the blood-brain barrier penetrability of many inhibitors is unclear. Our prediction is that ferroptotic and necroptotic inhibitors will be most effective. Consistent with this notion, the ferroptosis inhibitors deferoxamine 48 and N-acetylcysteine (unpublished results) provide significant functional recovery in some models of ICH.
